Nanobiotix S.A.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Nanobiotix S.A. (NBTX) is a late-stage clinical biotechnology company that pioneers the discovery, development, manufacture, and commercialization of disruptive physics-based nanotherapeutics, primarily focused on enhancing radiotherapy efficacy for cancer treatment. The company develops NBTXR3 (also known as JNJ-1900), a first-in-class radioenhancer nanoparticle designed to amplify radiation dose deposition within tumor cells without increasing exposure to surrounding healthy tissues; it also advances the Curadigm Nanoprimer platform through its subsidiary Curadigm, a nanotechnology solution that improves therapeutic bioavailability, reduces liver clearance, and boosts immune responses for gene therapies, mRNA vaccines, and other intravenous drugs. Nanobiotix targets solid tumors including head and neck, lung, esophageal, prostate, melanoma, and cutaneous cancers, with applications in immuno-oncology combinations such as anti-PD-1 therapies. Founded in 2003 and headquartered at 60 rue de Wattignies in Paris, France, with U.S. operations in Cambridge, Massachusetts, Nanobiotix conducts global clinical trials and maintains partnerships across Europe, the United States, and Asia. The company operates in the biotechnology sector, serving oncology patients, healthcare providers, and pharmaceutical collaborators through its proprietary NanoXray technology platform. In recent developments, Nanobiotix entered a global licensing agreement in 2023 with Janssen Pharmaceutica NV, a Johnson & Johnson company, for the co-development and commercialization of NBTXR3, focusing initially on head and neck and lung cancers while enabling expansion to other indications. In October 2025, the company secured a strategic royalty monetization agreement with Healthcare Royalty Partners for up to $71 million in non-dilutive funding, including a $50 million upfront payment, to extend cash runway into early 2028 and support milestones in NBTXR3 development. Additionally, in November 2025, Nanobiotix advanced its Curadigm Nanoprimer platform by filing four new patent applications, presenting preclinical data at PODD 2025 demonstrating enhanced immune responses with mRNA and peptide vaccines, initiating CMC activities, and expanding external collaborations via material transfer agreements. The company also completed majority-region sponsorship transfer of the Phase 3 NANORAY-312 trial in head and neck cancer to Johnson & Johnson and reported positive Phase 1 data for NBTXR3 in esophageal cancer and anti-PD-1 resistant melanoma.
Company News
Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Time to Sell?
Nanobiotix (NASDAQ:NBTX) Sees Large Volume Increase – Still a Buy?
NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer
NANOBIOTIX Provides First Half 2026 Operational and Financial Update
Voting Rights and Shares Capital of the Company
Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives Average Recommendation of “Moderate Buy” from Analysts
NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer
NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Voting Rights and Shares Capital of the Company
Voting Rights and Shares Capital of the Company
Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform
Nanobiotix: A Royalty-Backed Physics Platform Hidden Inside A Biotech
Voting Rights and Shares Capital of the Company
Nanobiotix Provides First Quarter 2026 Operational and Financial Update
Nanobiotix Joins the Euronext Tech Leaders Index
NANOBIOTIX Announces Closing of Global Offering
NANOBIOTIX Announces Full Exercise of Underwriters' Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris